T. Rowe Price Investment Management, Inc. Acquires 8.0% Stake in CG Oncology Inc (CGON)

On May 15, 2026, T. Rowe Price Investment Management, Inc. filed a Schedule 13G with the SEC, reporting a significant new ownership stake in CG Oncology Inc (CGON). As of the event date on March 31, 2026, the investment adviser reported beneficial ownership of 6,720,389 shares of common stock, representing an 8.0% stake in the company. This filing marks a major increase from a previous 0.0% position, indicating a substantial new entry into the issuer's equity. According to the filing, T. Rowe Price Investment Management, Inc. holds sole dispositive power over all 6,720,389 shares and sole voting power over 6,459,822 shares. The securities were acquired in the ordinary course of business and are not held for the purpose of changing or influencing the control of the issuer. The reporting person is a Maryland-based investment adviser and explicitly stated that this filing should not be construed as an admission of beneficial ownership for purposes other than regulatory compliance. The total value of the position is estimated at approximately $449.8 million based on the filing data.